NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NA
Post# of 325
(Total Views: 187)
Posted On: 10/11/2023 4:03:02 PM
NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports Rapid Pace of Enrollment in Potentially Pivotal Berubicin Study
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, is reporting enrollment of 229 participants in its ongoing potentially pivotal study evaluating Berubicin for the treatment of recurrent GBM, an aggressive and incurable form of brain cancer; the company expects to ultimately enroll 243 in the study. Participants are being enrolled in 46 clinical trial sites across the United States, Italy, France, Spain and Switzerland. According to the announcement, CNS Pharmaceuticals is on track to achieve value-driving milestones before the end of the year, including reporting topline results of interim analysis expected and completing enrollment in Q4 2023.
“The momentum in patient enrollment for this important study has frankly exceeded even our own high expectations,” said CNS Pharmaceuticals CEO John Climaco in the press release. “Recall that each patient who joins our study does so after their disease has recurred following the failure of standard of care treatment, an excruciating and deeply challenging moment in their life and their battle against glioblastoma. The confidence and trust these patients and their physician teams are demonstrating in our work is truly gratifying. With the sustained rapid pace of enrollment we’ve experienced here and in Europe, we are clearly on track to achieve complete enrollment of our study before year end. Perhaps even more importantly, we also expect to report results from the interim analysis later this quarter, with data derived from the robust sample set we have desired from the beginning as we seek to conclusively demonstrate Berubicin’s potential. As we continue to drive this study forward, we remain hopeful in our effort to address this devastating disease and potentially offering an effective treatment in GBM that is safe and well tolerated.”
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, is reporting enrollment of 229 participants in its ongoing potentially pivotal study evaluating Berubicin for the treatment of recurrent GBM, an aggressive and incurable form of brain cancer; the company expects to ultimately enroll 243 in the study. Participants are being enrolled in 46 clinical trial sites across the United States, Italy, France, Spain and Switzerland. According to the announcement, CNS Pharmaceuticals is on track to achieve value-driving milestones before the end of the year, including reporting topline results of interim analysis expected and completing enrollment in Q4 2023.
“The momentum in patient enrollment for this important study has frankly exceeded even our own high expectations,” said CNS Pharmaceuticals CEO John Climaco in the press release. “Recall that each patient who joins our study does so after their disease has recurred following the failure of standard of care treatment, an excruciating and deeply challenging moment in their life and their battle against glioblastoma. The confidence and trust these patients and their physician teams are demonstrating in our work is truly gratifying. With the sustained rapid pace of enrollment we’ve experienced here and in Europe, we are clearly on track to achieve complete enrollment of our study before year end. Perhaps even more importantly, we also expect to report results from the interim analysis later this quarter, with data derived from the robust sample set we have desired from the beginning as we seek to conclusively demonstrate Berubicin’s potential. As we continue to drive this study forward, we remain hopeful in our effort to address this devastating disease and potentially offering an effective treatment in GBM that is safe and well tolerated.”
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)CNS Pharmaceuticals Inc. (CNSP) Stock Research Links
Scroll down for more posts ▼